Hereditary Transthyretin Amyloidosis Market – Opportunities, Share, Growth and Competitive Analysis and Forecast 2029
Claim your 20% discount on Global Market Reports with code ONLINE20. Limited time only.
How Much Will The Hereditary Transthyretin Amyloidosis Market Be Worth By 2029?
The market for hereditary transthyretin amyloidosis has seen robust growth in the past few years. There is expected to be further growth from $1.36 billion in 2024 to $1.49 billion in 2025, demonstrating a compound annual growth rate (CAGR) of 9.3%. Factors contributing to this significant growth during the historical period include a surge in the occurrence of the disease, an escalation in research and development activities related to it, a rising count of cardiac amyloidosis instances, heightened awareness about the disease, and improvements in healthcare infrastructure.
The market for hereditary transthyretin amyloidosis is anticipated to experience robust growth in the coming years, rising to $2.09 billion by 2029 at a compound annual growth rate of 9.0%. Factors such as an aging population, increasing disposable incomes, a growing prevalence of hereditary transthyretin amyloidosis, burgeoning drug development, and an increase in genetic testing contribute to this projected growth. Key trends for this period encompass progressive treatment products, enhanced diagnostic methods, progress in drug innovation, the need for effective treatments, and forward strides in medical technology.
Get A Free Sample Of The Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=22003&type=smp
What External And Internal Drivers Are Influencing The Hereditary Transthyretin Amyloidosis Market?
The rise in the population of older individuals, those aged 65 and above, is anticipated to fuel the expansion of the hereditary transthyretin amyloidosis market. This segment of the population often necessitates exclusive healthcare resources and assistance as they age. There is a growth in this population due to extended life spans enhanced by better healthcare services and living standards. Hereditary transthyretin amyloidosis, or hATTR, particularly affects older adults by triggering progressive neuropathy and cardiomyopathy, which increase the occurrence of disease in them. For example, the Population Reference Bureau, a nonprofit organization in the US, predicted in January 2024 that the US population aged 65 and above is projected to surge from 58 million in 2022 to 82 million by 2050, denoting a 47% increment. Consequently, the burgeoning population of older adults is leading to the growth of the hereditary transthyretin amyloidosis market.
What Segmentation Insights Are Provided In The Hereditary Transthyretin Amyloidosis Market Research?
The hereditary transthyretin amyloidosismarket covered in this report is segmented –
1) By Type: Oral; Subcutaneous Injection; Other Types
2) By Drug Class: RNAi Agents (Patisiran); Small Interfering RNAs (siRNAs) (Vutrisiran)
3) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies
4) By Application: Hospital; Clinic; Other Applications
Subsegments:
1) By Oral: Tafamidis; Diflunisal; Experimental Oral Therapies
2) By Subcutaneous Injection: Patisiran; Inotersen; Vutrisiran
3) By Other Types: Intravenous Therapies; Gene Silencing Therapies; CRISPR-Based Therapies
Which Trends Are Likely To Redefine Growth Paths In The Hereditary Transthyretin Amyloidosis Market?
Leading companies in the hereditary transthyretin amyloidosis market are advancing novel treatments, such as RNA interference (RNAi) therapeutics, to target and decrease the production of transthyretin (TTR) protein. RNAi therapeutics utilize RNA interference technology to silence specific genes, thereby reducing the production of disease-causing proteins. For example, in October 2024, Alnylam Pharmaceuticals, Inc., a U.S.-based biopharmaceutical company, submitted a supplemental new drug application (sNDA) to the U.S. Food and Drug Administration (FDA) for Vutrisiran (AMVUTTRA) as a treatment for transthyretin amyloidosis with cardiomyopathy. This submission underscores its innovative RNAi therapeutic approach, designed to target and reduce TTR protein, a key factor in disease progression. Vutrisiran’s subcutaneous administration offers a more convenient and patient-friendly dosing regimen compared to traditional intravenous treatments, positioning it as a potentially transformative option for individuals with this serious condition.
Who Are The Leading Companies Driving The Hereditary Transthyretin Amyloidosis Market?
Major companies operating in the hereditary transthyretin amyloidosis market are Pfizer Inc., AbbVie Inc., Sanofi S.A., AstraZeneca plc, Novo Nordisk, Regeneron Pharmaceuticals Inc., Alexion Pharmaceuticals Inc., Alnylam Pharmaceuticals Inc., PTC Therapeutics Inc., Ionis Pharmaceuticals Inc., BridgeBio Pharma Inc., Akcea Therapeutics, Prothena Corporation plc, Intellia Therapeutics Inc., YoITech Therapeutics, Corino Therapeutics Inc., Attralus Inc., BSIM Therapeutics SA, Eidos Therapeutics, Autotac Bio Inc.
Access The Complete Report Here:
Which Geographic Regions Are Creating Strong Demand In The Hereditary Transthyretin Amyloidosis Market?
North America was the largest region in the hereditary transthyretin amyloidosis market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the hereditary transthyretin amyloidosis market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Customize Your Report Here:
https://www.thebusinessresearchcompany.com/customise?id=22003&type=smp
Browse Through More Reports Similar to the Global Hereditary Transthyretin Amyloidosis Market 2025, By The Business Research Company
Hereditary Cancer Testing Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/hereditary-cancer-testing-global-market-report
Hereditary Angioedema Therapeutics Global Market Report 2025
Hereditary Breast And Ovarian Cancer Syndrome Treatment Global Market Report 2025
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
